

Supplementary materials

Risk for Mortality in High vs Low Antiparkinsonian Therapy Dose During the First Year of Parkinson's Disease: A Real-World Study

Yael Barer • Olga Sánchez-Soliño • Gabriel Chodick • Meital Grabarnik-John • Shiran Naftelberg Blonder • Neta li Feurestein-Ganor • Lars Bergmann • Connie H. Yan • Sivan Gazit • David Arkadir

Y. Barer • G. Chodick • S. Gazit
Maccabi Institute for Research and Innovation, Maccabi Healthcare Services,
Tel Aviv, Israel

O. Sánchez-Soliño • L. Bergmann • Connie H. Yan
AbbVie Inc., North Chicago, IL, USA

G. Chodick
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

M. Grabarnik-John • S.N. Blonder • N. Feurestein-Ganor
AbbVie Inc., Hod Hasharon, Israel


D. Arkadir
Department of Neurology, Hadassah Medical Center and the faculty of medicine, the
Hebrew University and Hadassah, Jerusalem, Israel

Table S1 List of excluding diagnoses within the first 3 years post-PD first indication

Diagnosis
Other degenerative diseases of the basal ganglia (atrophy or degeneration): olivopontocerebellar atrophy (Dejerine-Thomas syndrome), pigmentary pallidal degeneration
Degenerative disease basal ganglia (e.g., PD)
Shy-Drager syndrome
Progressive supranuclear palsy
Multisystem atrophy
Secondary parkinsonism (e.g., parkinsonism due to drugs)
Abnormal involuntary movements, abnormal head movements, fasciculation, spasms NOS, and Tremor NOS
Neuroleptic-induced parkinsonism
Secondary PD
Secondary PD (i.e., pyramidal involvement)
Medication induced postural tremor

NOS not otherwise specified, *PD* Parkinson's disease

Fig. S1 Cohort selection.



LEDD levodopa equivalent daily dose, *MHS* Maccabi Healthcare Services, *PD* Parkinson's disease